Buy Zegalogue (dasiglucagon) Online For Sale

Zegalogue (dasiglucagon) is a medication used for the treatment of severe hypoglycemia in people with diabetes. It was approved by the US Food and Drug Administration in March 2021 and is marketed by Zealand Pharma.

Hypoglycemia occurs when blood sugar levels drop too low, often due to medication or insulin use. Severe hypoglycemia can lead to confusion, seizures, loss of consciousness, and even death. Currently available treatments for severe hypoglycemia require trained healthcare professionals to administer glucagon, a hormone that raises blood sugar levels, via injection.

Dasiglucagon is a novel, soluble glucagon analog that can be administered via a prefilled, single-use injector device. It works by stimulating the liver to release stored glucose, thereby increasing blood sugar levels and preventing the complications of severe hypoglycemia.

Clinical trials have shown promising results for dasiglucagon in the treatment of severe hypoglycemia in people with diabetes. In one study, dasiglucagon was able to raise blood sugar levels in 99% of cases within 15 minutes, compared to 100% for glucagon. The study also found that participants rated dasiglucagon as easier to use and more convenient than traditional glucagon.

Dasiglucagon is generally well-tolerated, with mild side effects such as nausea and vomiting. However, because it is a new medication, its long-term safety and effectiveness are still being evaluated.

Zegalogue is taken via a prefilled, single-use injector device that delivers a fixed dose of dasiglucagon. It is recommended for use in people with diabetes who are 6 years of age and older, weighing at least 16.5 pounds and have been prescribed glucagon by their healthcare provider.

While Zegalogue may offer a promising new treatment option for severe hypoglycemia, it is important to note that it should not replace low blood sugar management strategies and continuous blood glucose monitoring. Traditional glucagon injections and fast-acting carbohydrates (such as tablets or juice) should still be readily available as backup treatments in case of severe hypoglycemia.

In conclusion, Zegalogue (dasiglucagon) is a medication used for the treatment of severe hypoglycemia in people with diabetes. It is a novel, soluble glucagon analog that can be administered via a prefilled, single-use injector device. Clinical trials have shown promising results in raising blood sugar levels and improving convenience and ease of use compared to traditional glucagon injections. Zegalogue is generally well-tolerated, with mild side effects. It is recommended for use in people with diabetes who meet the weight and age criteria and have been prescribed glucagon by their healthcare provider. However, it should not replace or eliminate low blood sugar management strategies and continuous blood glucose monitoring.